Ratings JVM Co., Ltd.

Equities

A054950

KR7054950001

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-16 EDT			5-day change	1st Jan Change
28,500 ^KRW	-2.06%		-3.06%	+7.55%

03-12	JVM Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	JVM Co., Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The group's high margin levels account for strong profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company's attractive earnings multiples are brought to light by a P/E ratio at 11.23 for the current year.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
JVM CO., LTD.	+7.55%	243M	D
THERMO FISHER SCIENTIFIC	+12.15%	227B	B
DANAHER CORPORATION	+14.90%	197B	B-
INTUITIVE SURGICAL, INC.	+18.22%	141B	B-
BOSTON SCIENTIFIC CORPORATION	+29.15%	110B	A-
SIEMENS HEALTHINEERS AG	+0.53%	64.15B	A-
EDWARDS LIFESCIENCES CORPORATION	+16.92%	53.72B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+6.33%	51.75B	B+
AGILENT TECHNOLOGIES, INC.	+10.93%	45.2B	A
GE HEALTHCARE TECHNOLOGIES INC.	+5.87%	37.37B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders